fda glp-1 warning letters september 2025 news unleashes to firms selling compounded GLP-1s U.S. FDA | The American

Most people who use GLP-1 medications do not develop gastrointestinal paralysis

For type 2 diabetes , NICE guideline NG28 recommends considering GLP-1 agonists as an option when: Triple therapy with metformin and two other oral drugs is ineffective, not tolerated, or contraindicated The person has a BMI 35 kg/m (or 32.5 kg/m in people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity Insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities Treatment should be continued only if there is a beneficial metabolic response (HbA1c reduction of at least 11 mmol/mol [1.0%] and weight loss of at least 3% of initial body weight at 6 months)

Drugs that target the known pathophysiological processes and help to counteract or reverse them should be considered

Combining weight-loss products can increase side effects or interactions, and an outside program may duplicate clinical care or lab costs

concurrent use requires medical oversight to prevent dangerous interactions

The condition appears at higher doses